Actionable news
0
All posts from Actionable news
Actionable news in SAGE: SAGE THERAPEUTICS INC,

Sage Therapeutics stock surges 50% on positive trial results in postpartum depression

Sage Therapeutics Inc. SAGE, -1.73% shares surged 50% in premarket trade Thursday after the company said its postpartum depression therapy has positive results in two late-stage clinical trials. The therapy, brexanolone, met the primary endpoint in both trials, was generally well-tolerated by patients and was similarly safe as in earlier trials, Sage said. One clinical trial enrolled patients with moderate postpartum depression, while the other enrolled those with severe postpartum depression; in both trials, patients on the therapy had a reduction in a score assessing their depression levels as compared with the placebo from 60 hours after taking the therapy to 30 days later. Postpartum depression can occur late in pregnancy or within weeks of giving birth and, without treatment, symptoms -- which include depressed mood, crying, anxiety and feelings or worthlessness or shame -- can last many months or longer, according to the Mayo Clinic. An estimated 10% to 20% of women giving birth in the U.S. may be affected by postpartum depression, and there are currently no approved therapies for the condition, Sage said. Sage shares have dropped 27% over the last three months, compared with a 4% rise in the S&P 500 SPX, +0.14%


More